Chinese health officials announced Thursday that they have approved two new vaccines made by domestic companies for public use.
Read also: Anti-Covid vaccines: Moderna launches an assault on the South African variant
The vaccines, manufactured by Chinese company CanSino Biologics and a subsidiary of Sinopharm, have received a conditional green light after being found to be effective against Covid-19, the National Medicines Administration said.
A conditional authorization makes it possible to deploy emergency treatments on the market, in cases where clinical trials have yet to be continued but already indicate that these treatments will work.
The Wuhan Institute of Biologics, a subsidiary of the Sinopharm laboratory, assured that the efficacy rate of its vaccine was 72.51%. CanSino Biologics claims an efficacy rate of 65.28% for its vaccine 28 days after vaccination. The Chinese Medicines Authority said on Thursday that it would ask the two vaccine manufacturers to "
continue to conduct relevant research, meet the criteria for conditional authorization and submit their additional research results on time
."
